-
Mashup Score: 3AI, new technology major focus at 2024 AACE annual meeting - 2 hour(s) ago
Looking to the future will be a key theme at the American Association of Clinical Endocrinology 2024 annual meeting with a keynote lecture focused on AI and sessions examining guidance updates and new technology. This year’s AACE annual meeting will take place from Thursday to Saturday at the Hyatt Regency in New Orleans. The meeting will feature a wide range of sessions, including a
Source: www.healio.comCategories: General Medicine News, EndocrinologyTweet
-
Mashup Score: 0
Children with hypochondroplasia had an increase in growth velocity at 1 year of treatment with vosoritide, according to findings from a phase 2 trial. As Healio previously reported, the FDA issued an expanded indication for vosoritide (Voxzogo, BioMarin Pharmaceutical) to include children of all ages with achondroplasia with open epiphyses. In new findings published in eClinicalMedicine,
Source: www.healio.comCategories: General Medicine News, EndocrinologyTweet
-
Mashup Score: 5
Dietary supplements marketed online to promote weight loss commonly have inaccurate labels and may include unsafe ingredients for the public to use, according to findings published in JAMA Network Open.In a case series study, researchers purchased 30 dietary supplements and analyzed the products to confirm whether they consisted of the ingredients listed on the supplement facts label. Research
Source: www.healio.comCategories: General Medicine News, EndocrinologyTweet
-
Mashup Score: 0
Men who consumed more dietary vitamin E may be less likely to develop subclinical hypothyroidism and autoimmune thyroiditis, though no associations were observed among women, according to findings published in Thyroid. “At present, research on the relationship between vitamin E and thyroid dysfunction consists primarily of small-sample case-control studies or animal experiments,”
Source: www.healio.comCategories: General Medicine News, EndocrinologyTweet
-
Mashup Score: 3GLP-1 receptor agonist tied to similar thyroid cancer risk as DPP-IV, SGLT2 inhibitors - 6 day(s) ago
Adults who initiate a GLP-1 receptor agonist have a similar risk for developing thyroid cancer as those prescribed a DPP-IV inhibitor or an SGLT2 inhibitor, according to study findings published in The BMJ. “GLP-1 receptor agonist use was not associated with a substantially increased risk of thyroid cancer over a mean follow-up of 3.9 years,” Björn Pasternak, MD, PhD, associate
Source: www.healio.comCategories: General Medicine News, EndocrinologyTweet
-
Mashup Score: 2
The FDA granted fast track designation for an investigational parathyroid hormone 1 receptor agonist to treat hypoparathyroidism, according to an industry press release. Eneboparatide (Amolyt Pharma) is a therapeutic peptide designed to bind to the PTH receptor to produce sustained and stable levels of calcium in the blood, allowing the drug to control symptoms of hypoparathyroidism, and limit
Source: www.healio.comCategories: General Medicine News, EndocrinologyTweet
-
Mashup Score: 5
Dietary supplements marketed online to promote weight loss commonly have inaccurate labels and may include unsafe ingredients for the public to use, according to findings published in JAMA Network Open.In a case series study, researchers purchased 30 dietary supplements and analyzed the products to confirm whether they consisted of the ingredients listed on the supplement facts label. Research
Source: www.healio.comCategories: General Medicine News, EndocrinologyTweet
-
Mashup Score: 1
Low bone mineral density may be a risk factor for developing cirrhosis, according to study findings published in The Journal of Clinical Endocrinology & Metabolism. In the Hong Kong Osteoporosis Study, researchers followed 7,752 adults who had BMD measured through DXA scans. After a median follow-up of 18.43 years, 42 participants developed incident cirrhosis. The risk for cirrhosis declined
Source: www.healio.comCategories: General Medicine News, EndocrinologyTweet
-
Mashup Score: 11
The FDA granted integrated continuous glucose monitoring designation to a fully-implantable CGM, according to a press release. The Eversense E3 CGM (Senseonics Holdings and Ascensia Diabetes Care) received authorization to be marketed as an integrated CGM through the FDA’s De Novo pathway. The device is the first fully-implantable option in the category, according to the press release. The FDA
Source: www.healio.comCategories: General Medicine News, EndocrinologyTweet
-
Mashup Score: 1Racial discrimination during adolescence tied to metabolic syndrome for young Black adults - 9 day(s) ago
Black adolescents who face more racial discrimination may be more likely to have metabolic syndrome at age 31 years, according to findings published in JAMA Network Open. “Black adolescents who experience racial discrimination are predisposed to metabolic syndrome in young adulthood, which increases the risk for heart disease, diabetes and stroke,” Nia Heard-Garris, MD, MBA, MSc,
Source: www.healio.comCategories: General Medicine News, EndocrinologyTweet
🎙️#AACE2024 kicks off this morning at the Hyatt Regency in New Orleans. Healio spoke with program chair @ArchanaSadhu about some of this year’s highlights. Read more ⬇️ @TheAACE https://t.co/7m5Q6stKAI